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Neurobiology of Disease
Opposing Synaptic Regulation of Amyloid-Metabolism by
NMDA Receptors In Vivo
Deborah K. Verges,1 Jessica L. Restivo,1Whitney D. Goebel,1David M. Holtzman,1,2,3,4 and John R. Cirrito1,3,4
Departments of 1Neurology and 2Developmental Biology, 3Hope Center for Neurological Disorders, and 4Knight Alzheimer’s Disease Research Center,
Washington University School of Medicine, St. Louis, Missouri 63110
The concentration of amyloid- (A) within the brain extracellular space is one determinant of whether the peptide will aggregate into
toxic species that are important inAlzheimer’s disease (AD) pathogenesis. Some types of synaptic activity can regulateA levels. Herewe
demonstrate twodistinctmechanisms that are simultaneously activatedbyNMDAreceptors and regulate brain interstitial fluid (ISF)A
levels in opposite directions in the livingmouse. Depending on the dose of NMDA administered locally to the brain, ISF A levels either
increase or decrease. Lowdoses ofNMDA increase actionpotentials and synaptic transmissionwhich leads to an elevation in synapticA
generation. In contrast, high doses of NMDA activate signaling pathways that lead to ERK (extracellular-regulated kinase) activation,
which reduces processing of APP into A. This depression in A via APP processing occurs despite dramatically elevated synaptic
activity. Both of these synapticmechanisms are simultaneously active, with the balance between themdeterminingwhether ISFA levels
will increase or decrease. NMDA receptor antagonists increase ISF A levels, suggesting that basal activity at these receptors normally
suppresses A levels in vivo. This has implications for understanding normal Ametabolism as well as AD pathogenesis.
Introduction
Aggregation of amyloid- (A) as soluble oligomers and insolu-
ble plaques is central to the pathogenesis of Alzheimer’s disease
(Hardy, 2006). The concentration of monomeric soluble A is a
critical factor determining whether and when A will form these
toxic multimers (Lomakin et al., 1997). Thus, understanding the
mechanisms that regulate A levels has implications for under-
standing disease pathogenesis, aswell as developing anti-A ther-
apies. Amyloid plaques exist within the brain extracellular space.
While the initial seed of a plaque may form intracellularly or
extracellularly (Gouras et al., 2000; Meyer-Luehmann et al.,
2003), it appears that soluble Awithin the extracellular fluid, or
interstitial fluid, contributes to plaque growth (Yan et al., 2009).
Numerous studies have elucidated themechanisms bywhich am-
yloid precursor protein (APP) is cleaved by -secretase and
-secretase to produce A (for review, see Zhang et al., 2011);
however, the mechanisms that regulate how much A is pro-
duced are only partly understood.
Recent studies demonstrate that synaptic activity is a key reg-
ulator of A generation (Kamenetz et al., 2003). Seizures in APP
transgenic mice rapidly increase brain interstitial fluid (ISF) A
levels, whereas blocking neuronal activity with tetrodotoxin
(TTX) reduces A levels (Cirrito et al., 2005). Synaptic activity
leads to elevated clathrin-mediated endocytosis at the presynap-
tic terminal, which increases APP internalization and subsequent
A generation by -secretase and -secretase within endosomes
(Cirrito et al., 2008). A portion of the synaptically generatedA is
then secreted at the axon terminal (Wei et al., 2010), which is
capable of aggregating and forming A plaques (Harris et al.,
2010). The above studies are consistent with a synaptic mecha-
nism that directly leads to A generation and release from
neurons.
Second messenger signaling pathways that are induced by
neurotransmitter receptors can alter APP processing and there-
fore alter A production. For instance, muscarinic acetylcholine
receptors activate protein kinase C, which increases -secretase
cleavage of APP, thus reducing A levels in animal models and
humans (Nitsch et al., 2000; Hock et al., 2003; Caccamo et al.,
2006; Davis et al., 2010). NMDA receptors (NMDA-Rs) can also
modulate A levels. In addition to NMDA-Rs inducing synaptic
plasticity, they also cause nonamyloidogenic processing of APP
(Fazeli et al., 1994). Activation of these receptors increases
-secretase localization at synapses and reduces A production
(Gordon-Krajcer et al., 2002; Marcello et al., 2007). Depending
on the culture system used, some studies have found NMDA-Rs
to either increase or decrease A levels (Lesne´ et al., 2005;Hoey et
al., 2009).
Our studies in living mice demonstrate that NMDA-Rs can
either increase or decrease ISF A levels depending on the level of
receptor activation. Low doses of NMDA elevate ISF A levels by
increasing synaptic transmission and subsequent A generation,
whereas high doses of NMDA depress A by activating synaptic-
dependent signaling cascades that reduce amyloidogenic pro-
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cessing of APP. The balance between these mechanisms within a
single cell and within neuronal networks will determine whether
NMDA-Rs increase or decrease A in vivo.
Materials andMethods
Animals.All experimental procedures involving animals were performed
in accordance with guidelines established by the Animal Studies Com-
mittee at Washington University. We bred APP/PS1E9 (PS1APP)
hemizygous mice (The Jackson Laboratory) (Savonenko et al., 2003) to
wild-type C3H/B6 mice, and then aged the PS1APP/ offspring to
2.5–3.5 months for use in experiments. Animals were screened for the
PS1APP transgenes by PCR from tail DNA. Three-month-old C57BL6
mice were ordered directly from The Jackson Laboratory for use in ex-
periments. An equal number of males and females were used in each
experiment.
Compounds. All pharmacological agents were purchased from Sigma-
Aldrich unless otherwise noted. The NMDA-receptor antagonist 3-(2-
carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) was diluted into
saline and administered intraperitoneally at 20 mg/kg. FR180204,
PD98059, and ifenprodil were purchased from Tocris Bioscience.
In vivomicrodialysis. In vivomicrodialysis to assess brain ISF A in the
hippocampus of awake, freelymoving PS1APPmice was performed sim-
ilarly to previously described (Cirrito et al., 2003, 2005, 2008). This tech-
nique samples soluble molecules within the extracellular fluid that are
smaller than 30 kDa, the molecular-weight cutoff of the probe mem-
brane. A capable of entering the probe, likely to be predominantly
monomeric A, has been dubbed “exchangeable A” or “eA” (Cirrito
et al., 2003).
Under isoflurane volatile anesthetic, guide cannula (BR-style, Bio-
analytical Systems) were cemented into the left hippocampus
(bregma 3.1 mm, 2.5 mm lateral to mid-
line, and 1.2 mm below dura at a 12° angle).
Two-millimeter microdialysis probes were
inserted through the guides so the mem-
brane was contained entirely within the
hippocampus (BR-2, 30 kDa MWCO mem-
brane, Bioanalytical Systems). Microdialysis
perfusion buffer was artificial CSF (in mM:
1.3 CaCl2, 1.2 MgSO4, 3 KCl, 0.4 KH2PO4, 25
NaHCO3, and 122 NaCl, pH 7.35) contain-
ing 4% bovine serum albumin that was fil-
tered through a 0.1 m membrane. For
studies infusing BAPTA-AM via reverse mi-
crodialysis, the microdialysis perfusion buf-
fer had calcium replaced with magnesium.
Flow rate was a constant 1.0 l/min. Samples
were collected every 60–90 min with a refrig-
erated fraction collector into polypropylene
tubes and assessed for Ax–40 or Ax–42 by
sandwich ELISA at the completion of each
experiment. Basal levels of ISF A were de-
fined as the mean concentration of A over
6 h preceding drug treatment. Once basal ISF
A levels were established, PS1APP mice
were treated with a variety of compounds by
reverse microdialysis or by intraperitoneal
injection. For each animal, all ISF A levels
were normalized to the basal A concentra-
tion for that mouse. Experiments took place
under constant light conditions. Mouse ISF
A levels fluctuate in a diurnal rhythm if
mice are allowed to recover for 2 weeks after
microdialysis cannula placement and ex-
posed to 2 weeks of a 12 h/12 h light/dark
cycle before assessment of ISF A (Kang et
al., 2009). However, under constant light
conditions without entraining mice to a 12
h/12 h light/dark cycle after microdialysis
cannula placement, ISF A levels fluctuate
hourly by only 10–15% over a 3 d period.
Compounds delivered to the hippocampus via reverse microdialysis
were diluted in microdialysis perfusion buffer, which consisted of artifi-
cial CSF with 4% bovine serum albumin. Several compounds were deliv-
ered to the brain using reverse microdialysis. With this approach,
determining the absolute concentrations of a compoundwithin the brain
is difficult because of differences in efflux from the probe, diffusion
within the brain, and compound pharmacokinetics; therefore, only the
starting concentration of each compound is reported.
For the NMDA dose escalation study (Fig. 1A), each dose of com-
pound was administered for 3 h in ascending fashion. One group ofmice
received doses from 0.25–10M and another group received doses rang-
ing from 5 to 250 MNMDA.When delivered in this fashion, we grossly
estimate that the dose achieved within the brain is 50% of the actual
concentration within the microdialysis perfusion buffer.
Murine ISF A40 levels in wild type were assessed using a similar
protocol as PS1APP mice, except longer sample times of 6 h at a 0.5
l/min flow rate were necessary to concentrate ISF samples. For each
mouse, the basal concentration of A was established over a single 6 h
collection followed by two 6 h collections during treatment with either 1
M NMDA, 40 M NMDA, or CPP.
EEG recording. To record EEG activity, bipolar recording electrodes
(Teflon-coated, platinum–iridium wire, 0.0055 inch coated OD, A-M
Systems) were attached to the shaft of the microdialysis guide cannula
with Elmer’s Super-Fast Epoxy Resin (Elmer’s). Electrodes extended1
mm from the tip of the guide, so that the electrode tip was located at the
center of the 2 mm microdialysis membrane. EEG activity was assessed
using a P511K A.C. Preamplifier (Grass Instruments), digitized with a
DigiData 1440A Data Acquisition System (Molecular Devices), and re-
corded digitally using pClamp 10.2 (Molecular Devices). EEG traces are
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Figure 1. Differential dose-dependent effect of NMDA-R signaling on ISF A levels in vivo. A, Direct NMDA infusion into the
brain via reverse microdialysis caused a differential dose-dependent change in ISF A levels. Mean A concentrations during
hours 2–3 of a total 3 h treatment at each dose. At NMDA doses of 0.25–1M, there were significant increases in ISF A40 with a
32 15.2% elevation at 1M compared to basal levels (p 0.01). At NMDA doses of 20–250M, there was a dose-dependent
decrease in ISF A40 levels. Forty micromolar NMDA reduced A40 levels by 49.3 4.3% with a maximal depression of 76.2
1.8%at 250MNMDA.n6–10per dose.B, A subset ofmice also hadA42 levels assessedduringNMDA infusion. One and forty
micromolarNMDAalteredA42 levels by increasing40.09.9%(p0.01) anddecreasing43.35.7%(p0.01), respectively
(n 6 per group). C, Representative EEG trace from a PS1APP/ administered escalating doses of NMDA by reverse microdi-
alysis. EEG activity recorded within the hippocampus showed synchronous spikes in activity at 1 and 40M NMDA (arrows) and
intermittent epileptiform activity at 250M NMDA (arrowhead). D, Forty micromolar NMDAwas administered to the hippocam-
pus for 6 h and then removed from the microdialysis perfusion buffer. During the next 30 h of sampling, ISF A levels gradually
returned to baseline levels; 94.3 13.5% compared to basal levels in each mouse (n 5). **p 0.01, ***p 0.001.
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representative data from one animal undergoing each drug treatment so
that traces can be directly compared between treatments. The frequency
of synchronous spikes in EEG activity were analyzed using pClamp 10.2.
Positive-going activity that exceeded three times the SD of the amplitude
under basal conditions were marked as synchronous spikes in activity.
A ELISAs. ISF A levels were assessed using sandwich ELISAs as
described previously (Kim et al., 2009). Briefly, a mouse anti-A40 anti-
body (mHJ2) or mouse anti-A42 antibody (mHJ7.4) was used to cap-
ture and a biotinylated central domain antibody (mHJ5.1) was used to
detect, followed by streptavidin-poly-HRP-40 (Fitzgerald Industries).
All ELISA assays were developed using Super Slow ELISA TMB (Sigma)
and absorbance read on a BioTek Epoch plate reader at 650 nm. These
assays equally recognize human and murine A so the same assays were
used for samples generated in PS1APP human APP transgenic mice and
wild-type mice. The standard curves for each assay, however, used either
human or mouse A peptide.
Western blots. Three-month-old PS1APP mice treated with vehicle or
CPP by intraperitoneal injection and 8 h later were killed by cardiac
perfusion with chilled saline with 0.3% heparin and the hippocampus
microdissected and snap frozen on dry ice. Hippocampal tissue was ho-
mogenized by sonication in 10:1 volume:wet weight of 150 mMNaCl, 50
mMTris, pH 7.4, 0.5%deoxycholic acid, 0.1% SDS, 1%Triton X-100, 2.5
mM EDTA, and protease inhibitors.Western blotting for full-length APP
was performed using 4–12% Bis-Tris NuPAGE gels (Invitrogen) under
reducing conditionswith 15g of protein loaded per lane. Nitrocellulose
blots were probed with rabbit anti-APP directed against the C terminus
of APP (Invitrogen), followed by donkey anti-rabbit antibody reab-
sorbed against mouse IgG and conjugated to peroxidase (Santa Cruz
Biotechnology). Gels were stripped and reprobed with rabbit anti-
tubulin (Sigma) as a loading control protein. Bands were detected with
Lumigen-TMA6 (GEHealthcare) and captured digitally using the Kodak
ImageStation 440CF. Densitometry was performed using the Kodak 1D
Image Analysis software and each band normalized to tubulin signal in
each lane.
ERK pathway multiplex assay. Hippocampal tissue was isolated from
CPP (20 mg/kg, i.p.) and vehicle-treated PS1APP mice (8 h treatment)
were then lysed in the EpiTag Cell Lysis Kit (Novagen) by mechanical
homogenization. ERK2 total protein and phosphorylated forms of
MEK1/2 and ERK2 were measured together using the WideScreen Epi-
Tag ERK Pathway Panel I (Novagen) with concentrations calibrated
against the EpiTag ERK Pathway Standards Mix. Bead fluorescence was
quantified using the xMAP Luminex platform.
Secretase assays. Enzymatic activity of -secretase and -secretase was
measured using FRET-based cleavage assays (R&DSystems).Hippocam-
pal tissue was isolated from CPP (20 mg/kg, i.p.) and vehicle-treated
PS1APP mice (8 h treatment) were then lysed in Cell Extraction Buffer
(Novagen) by mechanical homogenization. Cell extracts were incubated
with secretase-specific peptides conjugated to the reporter molecules
EDANS andDABCYL for 15–30min. EDANS fluorescence was read on a
Synergy 2 microtiter plate reader (BioTek).
Statistics. Data in figures are presented as mean  SEM. All statis-
tical analysis was performed using Prism version 5.04 for Windows
(GraphPad). Statistical analysis to compare the mean values for mul-
tiple groups was performed using a one-way ANOVA with correction
for multiple comparisons. Comparison of only two groups was per-
formed using a two-tailed unpaired t test. Analysis of effects of drug
versus vehicle treatment over time was done with a repeated-
measures two-way ANOVA with correction for multiple compari-
sons. Values were accepted as significant if p  0.05.
Results
Differential dose-dependent effect of NMDA-R signaling on
ISF A levels in vivo
A is produced primarily within neurons and secreted into the
brain extracellular fluid, or ISF. We used a brain microdialysis
technique to specifically measure dynamic changes in ISF A
levels over time in living mice (Cirrito et al., 2003, 2008). This
technique permits serial sampling of ISF A up to every hour for
several days while themice are awake and have freedom ofmove-
ment. Agents can be administered to these mice either by intra-
peritoneal injection or can be administered directly to the brain
by adding the compound to the microdialysis probe perfusion
buffer, a technique called reverse microdialysis. Compounds
within the perfusion buffer diffuse out of the probe and into the
brain, simultaneous with A diffusion into the probe, allowing
for a continuous application of drug with minimal tissue disrup-
tion and while bypassing the blood–brain barrier.
Three- to four-month-old PS1APP hemizygous transgenic
mice were implanted with hippocampal microdialysis probes
(Cirrito et al., 2003). Mice at this age do not yet contain A
deposits, thus allowing us to study normal brain Ametabolism
without complicating factors, such as A aggregates, which could
alter the equilibrium and metabolism of extracellular A. The
basal ISF A concentration for eachmouse was established over a
6 h period followed by treatmentwith a dose escalation ofNMDA
by reversemicrodialysis. The concentration of NMDAwithin the
microdialysis probe was gradually stepped from 0.25 to 250 M
with exposure to each dose lasting 3 h. Administration of 0.25 to
1 M NMDA significantly elevated ISF A40 levels by 30–75%
over basal levels with the peak increase at 0.5 M NMDA (Fig.
1A). Doses between 2 and 10 M NMDA had no effect on ISF
A40 levels, whereas doses of 20 M and above caused a signifi-
cant depression in ISF A levels. For instance, 40 M NMDA
caused an50% decrease in ISF A. Levels of A42 were affected
in a similar way as A40 by both the low and high doses of NMDA
(Fig. 1B).
To confirm that NMDA-Rs underlie the dose-dependent reg-
ulation of A metabolism (Fig. 1A), we performed a similar
dose–response study using homoquinolinic acid (HQ), another
selective agonist for NMDA-Rs (Grimwood et al., 2002). Sim-
ilar to NMDA, low doses of HQ (0.25–1 M) increased ISF A
levels, whereas high doses of HQ (5–20 M) depressed A
levels significantly. The peak increase in ISF A occurred at
0.25 M HQ (increased by 50.0  2.7% of basal levels). Infu-
sion of 20 M HQ reduced ISF A by 54.5  2.3% of basal
levels (n  5 per group).
Interestingly, other types of glutamate receptors can also
modulate ISF A levels. Metabotropic glutamate receptor 2/3
agonists suppress ISF A levels (Cirrito et al., 2005), whereas
antagonists increase A (Cirrito et al., 2008). Baseline AMPA
receptor (AMPA-R) activity increases ISF A levels in vivo. Infu-
sion of an AMPA-R antagonist, NBQX (10 M by reverse micro-
dialysis), into the hippocampus suppressed ISF A levels by
21.7  1.5% compared to vehicle-treated mice (p  0.0002).
These receptors are responsible for much of the excitatory neu-
rotransmission within the brain, so blocking AMPA-Rs reduces
synaptic activity, which likely reduces synaptic A generation
(Cirrito et al., 2005).Whether similar or distinct mechanisms are
used by NMDA-Rs and other types of glutamate receptors to
modulate ISF A levels are unknown.
Our original hypothesis was that this excitatory neurotrans-
mitter would depolarize neurons, increase synaptic activity, and
consequently elevate brain ISFA levels. In our studies, lowdoses
of NMDA resulted in effects consistent with this hypothesis; low
doses of NMDA infused directly into the brain elevated synaptic
transmission and A generation within hours. Surprisingly,
however, as we gradually increased the dose of NMDA, there was
a dose-dependent decrease in ISF A levels that was contrary to
the initial hypothesis.
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A is reduced despite dramatic elevations in neuronal activity
Neurotransmitter receptors can have paradoxical effects on neu-
ral networks, especially in the case of receptors that desensitize
following intense activation or in the case of excitatory receptors
on inhibitory interneurons. To determine how various doses of
NMDA affected neuronal activity, we assessed extracellular field
potentials, or depth EEG, within the hippocampus of mice being
administered NMDA via reverse microdialysis (Fig. 1C). The
EEG recording electrodes were attached directly to the microdi-
alysis guide cannula to record electrical activity at the same loca-
tion that NMDAwas administered and Awas collected (Cirrito
et al., 2005). Under basal conditions, there were synchronous
spikes in EEG activity at a frequency of 0.03 0.007Hz (mean
SEM; n  5). One micromolar NMDA had a small, but signifi-
cant, effect on recorded EEG; new synchronous spikes in activity
occurred with a frequency of 0.1 0.013 Hz (p 0.05). Increas-
ing the dose to 40MNMDA had amore dramatic effect on EEG
activity with spikes in activity occurring at 0.23  0.03 Hz (p 
0.01). This elevated activity, however, was subthreshold for epi-
leptiform activity. At doses of 250 M NMDA, EEG activity was
dramatically higher with spikes in activity occurring at 1.7 0.13
Hz (p 0.0001) and epileptiform activity occurring several times
during a 3 h administration though this activity did not generalize
to result in a behavioral manifestation. Very low doses of NMDA
elevated ISF A levels, which is consistent with our previous
publications of a presynaptic generation of A that is tightly cou-
pled to synaptic transmission (Cirrito et al., 2005, 2008). The
reduction in A by higher doses of NMDA, however, did not
appear to be due to this synaptic generation of A given that even
in the presence of hippocampal seizures, ISF A levels were still
dramatically reduced.
The EC50 of NMDA at NMDA-Rs is 35M in vitro (Patneau
and Mayer, 1990). Delivered by reverse microdialysis in vivo,
NMDA concentrations of 0.25–1 M (or lower within the pa-
renchyma) should activate only a very small percentage of
receptors [estimated 1% bound at 1 M NMDA based on Pat-
neau and Mayer (1990)]. Given that almost all neurons within
the brain express NMDA-Rs, this small percentage is likely a
large number of receptors that are activated. In support of this,
1 M NMDA delivered by reverse microdialysis increases neu-
ronal activity as detected by increased synchronous spikes in
EEG recordings (Fig. 1C).
Reductions in ISF A are not due to neuronal injury
Glutamate receptor overstimulation is known to cause excito-
toxic injury to neurons (Olney and Sharpe, 1969).We postulated
that the decrease in ISF A could be due to cell death as opposed
to a true change in A metabolism. We infused 40 M NMDA
into the hippocampus for 6 h, which caused a rapid decrease in
ISF A (Fig. 1D). At the end of 6 h of treatment, NMDA was
removed from the microdialysis perfusion buffer and ISF A
levels were measured for an additional 36 h. During this washout
period, ISFA levels gradually returned to baseline levels (96%of
baseline at 30 h from the beginning of the washout period). The
complete recovery of A levels strongly suggests that the depres-
sion in A by 40 M NMDA was not caused by an excitotoxic
lesion. In addition, FluoroJade B staining around themicrodialy-
sis probe, to detect degenerating cells, did not show increased
reactivity in mice administered 40 M NMDA (data not shown).
Studies described laterwill demonstrate that the depression inA
by 40 M NMDA can be blocked with several agents, further
suggesting the depression in A is caused by altered cellular me-
tabolism as opposed to neuronal injury. This is also consistent
with other publications that have delivered similar concentra-
tions of NMDA to the brain via reverse microdialysis and de-
tected physiological alterations as a consequence (Duva et al.,
2001).
NMDA-R antagonists increase ISF A levels
To determine how endogenousNMDA-R signaling alters A lev-
els, we administered CPP, a selective NMDA-R antagonist, sys-
temically to PS1APP transgenicmice. CPP (20mg/kg i.p.) caused
a significant 75% increase in ISF A levels over 3 h, which re-
mained high until at least 10 h after treatment compared to
vehicle-treated mice (Fig. 2A). This demonstrates that basal
NMDA-R signaling within the hippocampus normally sup-
presses A levels. Since CPP does not cause excitotoxicity, this is
also further evidence that modulation of A levels is a physiolog-
ical response to NMDA-R signaling and not due to degenerating
neurons.
Paradoxically, low doses of exogenous NMDAhave the oppo-
site effect on A than endogenous NMDA signaling has, suggest-
ing that a separate population of receptors underlie the two
phenomenon. To remove the basally active NMDA-Rs for the
experimental system, we infused MK801, a noncompetitive use-
dependent NMDA-R antagonist, into the hippocampus. This
compound will only block NMDA-Rs that have open channels
when the drug is present (Huettner and Bean, 1988; Ivanov et al.,
2006). Similar to CPP, MK801 increased ISF A levels by 60%
(Fig. 2B). After 60 min of administration, MK801 was removed
from the microdialysis perfusion buffer to wash out existing
compound from the brain for 90 min. One cohort of PS1APP
Figure 2. NMDA-R antagonists increase ISF A levels. A, NMDA-R antagonist CPP (20mg/kg i.p.) increased ISF A levels by 77.4 28.7% compared to vehicle-treated (saline) PS1APPmice at
10 h after treatment (p 0.05, n 6 per group). B, MK801 (100M by reverse microdialysis), a use-dependent NMDA-R antagonist, was infused into the hippocampus for 60 min followed by a
90minwashout and reapplication of MK801, 1M NMDA, or 40M NMDA for 8 h (n 5 per group). MK801 alone significantly increased ISF A40 by 60.7 16.6% (p 0.05) compared to basal
levels. One micromolar NMDA increased ISF A by 281.7 60% (p 0.01), whereas 40M NMDA reduced A by 49.6 7.1% (p 0.05) compared to basal levels. C, Infusion of the NR2B
subunit-selective antagonist, ifenprodil (50M), alone increased ISF A40 by 19.3 3.3% (p 0.05) compared to basal levels. Cotreatment of ifenprodil and either 1M NMDA or 40M NMDA
increased A by 51.6 12.2% (p 0.05) and decreased A by 62.5 7.9% (p 0.0001; n 5–6 per group), respectively. Data are presented as mean SEM. ***p 0.001.
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mice had MK801 reapplied after the washout period. In these
mice, ISF A levels did not have an additional change, suggesting
that during the washout phase no new NMDA-Rs were recruited
to regulate A metabolism. A second and third cohort of mice
were administered either 1 or 40 M NMDA after the washout
period, which caused an increase in A by 280% and a decrease
by 50%, respectively (Fig. 2B). This suggests that exogenous ap-
plication of NMDA activates a separate set of receptors, likely on
separate neurons, from those used under basal conditions to reg-
ulate Ametabolism.
A functional NMDA-R consists of two NR1 subunits (out of
eight known subunits) and twoNR2 subunits (out of four known
subunits). The combination of subunits within each receptor im-
pacts the receptor’s properties, such as kinetics and localization.
For instance, NR2B-containing receptors can be localized ax-
onally and at extrasynaptic sites (Ko¨hr, 2006). To determine
whether NR2B receptors modulate A metabolism, we infused
ifenprodil, a NR2B-selective inhibitor, into the hippocampus.
Ifenprodil alone increased ISF A levels by 20% (Fig. 2C). Pre-
treatment with ifenprodil marginally affected the change in A
metabolism by either low- or high-dose NMDA (Fig. 2C). This
suggests that NR2B-containing receptors likely account for a rel-
atively small portion of synaptic-dependent Ametabolism.
NMDA-Rmodulation alters endogenous murine A levels
As with any transgenic animal model, a concern is that an obser-
vation could be due to overexpression of a protein as opposed to
a normal cellular process. Using microdialysis, we established
basal ISF murine A levels in the hippocampus of young wild-
type C57BL6 mice and then administered either 1 M NMDA or
40 M NMDA for 4 h by reverse microdialysis. A low dose of
NMDA caused a significant 45% increase in ISF A, whereas a
high dose caused a 50% reduction in A (Fig. 3). Similarly, CPP
caused a 50% increase in ISF murine A levels in C57BL6 mice
(Fig. 3). These data demonstrate that NMDA-Rs modulate phys-
iological Ametabolism.
Action potentials are only required for NMDA-dependent
elevations in ISF A
To determine whether NMDA-dependent changes to A were
primarily due to depolarization/action potentials or to signaling
cascades activated by these receptors, we pretreated mice with
TTX for 15 h and then coinfused TTXwith either 1MNMDAor
40 M NMDA into the hippocampus for 8 h (Fig. 4A). In the
presence of TTX, infusion of NMDA will activate NMDA-Rs
normally; however, the neuronal response is limited to local ac-
tion of NMDA-Rs. TTX alone reduced A levels by 40% similar
to previous reports (Kamenetz et al., 2003; Cirrito et al., 2005).
TTX completely blocked the increase in ISF A levels caused by 1
M NMDA (Fig. 4B); however, 40 M NMDA still caused a sig-
nificant 45% reduction in ISF A levels compared to TTX treat-
ment alone. As expected, even though NMDA-Rs were activated,
TTX blocked the downstream neuronal activity caused by both
concentrations ofNMDAasmeasured by hippocampal EEG (Fig.
4C). This suggests that low doses of NMDA require action poten-
tials to increase A generation (Cirrito et al., 2005, 2008), but in
contrast, reduction of A by high doses of NMDA do not.
Calcium is necessary for NMDA-dependent changes of
ISF A
NMDA-Rs are cation channels that are primarily permeable to
sodium and calcium influx. Given that calcium can have a mul-
titude of effects within a cell, we determined whether calcium
entry was responsible for the NMDA-dependent changes in ISF
A. Basal ISF A levels were determined in PS1APP mice fol-
lowed by administration of vehicle or BAPTA-AM, a calcium
chelator, by reverse microdialysis for 6 h (Fig. 5A). BAPTA-AM
alone increased ISF A levels by 27% by the end of treatment,
suggesting that some basal calcium signaling normally lowers ISF
A. Beginning at hour 7, BAPTA-AM was coadministered with
either 1 M NMDA or 40 M NMDA for an additional 8 h. One
micromolar NMDA only increased ISF A levels by 10% in the
presence of BAPTA-AM when normalized to BAPTA-AM treat-
ment alone (Fig. 5B). This increase could be driven by residual
presynaptic cycling supported by any unchelated calcium that
remains. BAPTA-AM also reduced the effect of 40 M NMDA.
Forty micromolar NMDA only reduced ISF A by 30% in the
presence of the calcium chelator when normalized to pretreat-
ment levels. Not surprisingly, these data suggest that calcium is at
least partially responsible for both the elevation and depression of
ISF A by NMDA. In vivo, it is unlikely that all free calcium is
buffered by BAPTA-AM; therefore, it is still possible that NMDA
entirely requires calcium to modulate A levels.
ERK signaling is required for NMDA-dependent depression
of ISF A levels
Calcium influx through NMDA-Rs can lead to activation of sev-
eral secondmessenger signaling pathways, including the extracel-
lular regulated kinase (ERK) pathway (Bading and Greenberg,
1991; Kurino et al., 1995; Xia et al., 1996; Ivanov et al., 2006). ERK
is amitogen-activated protein kinase (MAPK) that is activated by
a wide variety of extracellular ligands (Boulton and Cobb, 1991).
In this signaling cascade, an extracellular ligand leads to activa-
tion of Raf kinase, which results in sequential phosphorylation of
MEK and then ERK, which is the active form of this kinase. Phos-
phorylated ERK (pERK) acts within the cytoplasm to phosphor-
ylate other proteins and alter their function or it translocates to
the nucleus to alter gene transcription.
In PS1APP hemizygous mice, we blocked the ERK signaling
pathway by infusing agents that inhibit eitherMEK (PD98059) or
ERK (FR180204) through the microdialysis probe. These inhibi-
tors alone increased ISF A levels by 58% and 42%, respectively
(Fig. 5C). Interestingly, however, in the presence of either inhib-
itor, 40MNMDA no longer decreased ISF A levels but instead
Figure 3. Effect of NMDA-R modulation on endogenous murine A levels. ISF A levels in
wild-type C57BL6 mice increased by 44.2 11.7% (*p 0.05) and decreased by 51.4
12.3% (p 0.01) compared to basal levels in response to 1 and 40MNMDAdelivered into the
hippocampus by reverse microdialysis (n 5–6 per group). CPP (20mg/kg, i.p.) elevated A
levels by 38.3 10.7% (**p 0.01) compared to basal levels in each mouse (n 5). Data
presented as mean SEM.
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dramatically increased ISF A levels by twofold and threefold
compared to basal levels in each mouse (Fig. 5D). Inhibitors of
two different points of the ERK signaling cascade block the effect
of 40MNMDA, strongly suggesting that the ERK signaling cas-
cade is required for the NMDA-dependent reduction in ISF A. In
contrast, an inhibitor of calcium/calmodulin kinase (CaMK), KN-
93, did not block the reduction in ISF A by 40 M NMDA.
Neither the MEK nor ERK inhibitor affected the increase in
ISF A levels by 1 M NMDA (data not shown), demonstrat-
ing that ERK signaling is only required for depression of ISF
A but not action potential-mediated synaptic A generation.
The remarkable elevation in A by coadministration of ERK
pathway inhibitors and 40 M NMDA was likely due to synaptic
mechanisms that generate A as a consequence of synaptic trans-
mission (Cirrito et al., 2005). To test this hypothesis directly, we
pretreated PS1APP mice with TTX and then FR180204 to block
action potentials and ERK signaling, then cotreated with 40 M
NMDA. In this setting, ISF A levels did not change compared to
pretreatment levels (Fig. 5E), suggesting that blocking the ERK
signaling that reduces APP processing into A as well as blocking
synaptic A generation is sufficient to prevent NMDA from al-
tering ISF A levels at all.
Only select ERK activators regulate Ametabolism
Numerous receptors and signaling pathways can converge to acti-
vate ERK, which in turn can have a multitude of downstream tran-
scriptional or protein targets. ERK activation and activity, however,
is highly regulated and can have very precise biological responses in
large part due to cellular context, scaffold proteins, and compart-
mentalization where it is activated (for review, see Pouysse´gur et al.,
2002). We determined the extent that other ERK activators would
impact A metabolism. Using reverse microdialysis, we infused a
Trk-B receptor agonist [7,8-dihydroxyflavone (DHF)], a glucocor-
ticoid receptor ligand (allopregnanolone), or a serotonin recep-
tor ligand (serotonin) into the brain (Fig. 5F). In addition to the
many effects these pathways have within a neuron, ERK is also
activated (Hetman et al., 1999; Basta-Kaim et al., 2007; Cowen,
2007). Interestingly, neither activation of Trk-B receptors nor
glucocorticoid receptors altered ISF A levels. Infusion of sero-
tonin however significantly reduced ISF A levels by 20% (Fig.
5F). The particular cellular cues, cofac-
tors, and scaffold proteins that underlie
this downstream substrate specificity are
still unknown.
NMDA-R signaling alters secretase
cleavage of APP
We sought to determine the mechanisms
by which NMDA-R signaling alters A
levels. To alter NMDA-R signaling uni-
formly throughout the brain, PS1APP
were administered vehicle or the
NMDA-R antagonist CPP by intraperito-
neal injection. Eight hours after treat-
ment, tissue was harvested and processed
for a Luminex bead-based assay to mea-
sure various components of the ERK cas-
cade. CPP did not alter total ERK2 (Fig.
6A) or ERK1 (data not shown) protein
levels; however, the phosphorylated active
forms of both the ERK2 andMEK1/2were
significantly reduced (Fig. 6A). Phospho-
ERK1 protein levels were not detectable
with this assay. Full-length APP levels were unaffected by CPP
administration (Fig. 6B); however, APP C-terminal fragment
(CTF)- was significantly reduced by 15.2 2.1% compared to
vehicle-treated mice (p  0.05; n  8 per group), while APP
CTF- was unaffected.
ERK signaling has been shown to increase -secretase activity
(Kojroetal., 2006)anddecrease-secretaseactivity (Kimetal., 2006;
Tung et al., 2008), both of which are consistent with the depression
in ISFA causedby40MNMDA.Wemeasured enzymatic activity
of -secretase and -secretase in brain homogenates from the CPP
and vehicle-treated PS1APP mice using fluorometric cleavage as-
says. Eight hours after CPP treatment, -secretase activity was sig-
nificantly reduced,whereas-secretase activitywasunalteredwithin
the hippocampus (Fig. 6C); enzymatic activity was consistent
with our observed changes in APP-CTFs. Whether ERK causes a
posttranslational or transcriptional effect to alter -secretase ac-
tivity in vivo is still unclear. Interestingly, presenilin-1 (PS1) pro-
tein levels were elevated as assessed by Western blot (Fig. 6B).
Both of these changes in APP processing are consistent with an
elevation in ISF A levels following NMDA-R antagonist
treatment.
Discussion
The relationship between synaptic activity and regulation of A lev-
els is complex. A single neurotransmitter receptor, such as
NMDA-R, can simultaneously activatemultiplemechanismswithin
a cell to differentially regulate A generation. Calcium influx
through these receptors depolarizes and excites neurons leading to
synaptic transmission, which is closely linked to synaptic A gener-
ation. Calcium also acts as a second messenger. When sufficient
calcium levels are reached through high levels of NMDA-R activity,
the ERK signaling cascade is activated, which depresses APP pro-
cessing intoA, likely via enhancing-secretase cleavage activity.
Our studies administering NMDA to the hippocampus demon-
strate that this neurotransmitter system can have dramatic effects
on A levels with up to a 75% reduction at the highest doses of
NMDA. Given that NMDA-R antagonists, in both APP trans-
genic and wild-type mice, elevate A levels, it appears that basal
signaling through these receptors contributes to normal suppres-
sion of A generation.
Figure4. Presynaptic versuspostsynapticmechanisms that regulateAmetabolism.A, TTX (5M)wasdelivered continuously
into thehippocampusby reversemicrodialysis for 16h followedby coinfusionwith either 1 or 40MNMDA.B, In this setting, 1M
NMDAhadno effect on ISF A levels,whereas 40MNMDA reduced ISF A levels by 44.4 3.1%compared to levels during hour
16 of TTX-treatment alone (***p 0.001). (n 5–6 per group). C, Representative EEG traces during a dose escalation of NMDA
during TTX treatment. TTX (5M) was delivered for 16 h, followed by 3 h each of 1M and then 40M NMDA (n 3mice). Data
presented as mean SEM.




Low doses of exogenous NMDA depolar-
ize neurons, elevate synaptic transmis-
sion, and increase A generation and
secretion (Fig. 7A). Recruitment of
NMDA-Rs and neurons that are not ac-
tive under basal conditions appear to be
responsible for this increase in A. While
this can occur via a presynaptic mecha-
nism that requires clathrin-mediated en-
docytosis (Cirrito et al., 2008), other areas
of a neuron may also contribute to this
increase in generation. In contrast, high
doses of NMDA activate the ERK signal-
ing pathway, which downregulates APP
processing into A despite increased syn-
aptic activity (Fig. 7B). This depression in
A appears to be in part due to enhanced
-secretase enzymatic activity. We pro-
pose that at low levels of NMDA-R activa-
tion, very little ERK is activated; thus, the
balance is shifted so that synaptic trans-
mission drives A generation. Strong
NMDA-R activation, however, recruits
ERK, which reduces APP processing into
A. The balance between enhancing A
generation and depressing APP process-
ing determines the total amount of A
that a neuronwill produce at a given time.
Midrange doses of NMDA (Fig. 1A)
(2–10 M) had no net change in ISF A
levels; this likely represents an equal bal-
ance of these competing pathways. Under
normal conditions, basal NMDA-R sig-
naling is sufficient to drive ERK activation
and suppress AP processing into A. This
likely occurs in a subpopulation of neu-
rons where either baseline NMDA-R ac-
tivity is high or at a set of NMDA-Rs that
are particularly capable to activating ERK.
Neuronal depolarization and synaptic
transmission lead to APP endocytosis and
A generation and then secretion (Cirrito et al., 2008). This ap-
pears to be a normal metabolic pathway for A generation. In-
creasing synaptic activity in a cell may simply drive more APP
through this pathway and therefore generate more A. In con-
trast, changing APP processing via secretase activity alters the
ability of a cell to produce A. APP is primarily cleaved by
-secretase within the secretory pathway (Lammich et al., 1999),
which is upstream of endocytic events that lead to A generation
(Koo and Squazzo, 1994). Thus, in the presence of 40MNMDA,
elevated -secretase activity cleaves APP, which reduces the sub-
strate available for later A generation within endosomes (Fig.
1A). When ERK signaling is inhibited, however, 40 M NMDA
has no effect on the APP substrate; thus, a dramatic increase in
synaptic A generation is unmasked (Fig. 5C).
Basal NMDA-R and ERK activity lowers ISF A levels
Administration ofNMDA-R antagonists or inhibitors of the ERK
signaling cascade block steady-state activity and increase ISF A
levels. This suggests that there is a physiologic suppression of A
levels byNMDA-Rs and by ERK in vivo. NR2B-containing recep-
tors appear to account for only a small portion of the basal sup-
pression in A since ifenprodil (NR2B-selective) only increases
Aby 20%,whereas broader antagonists such asMK801 andCPP
and increase A by 60–75%.
NMDA receptors, ERK, and Ametabolism
Two very similar studies have assessed the role of NMDA-Rs in
A metabolism in neuronal culture and produced conflicting
evidence. Lesne´ et al. (2005) determined that NMDA increased
A production and A levels in primary neuronal cultures by
reducing -secretase activity. In contrast, Hoey et al. (2009)
found thatNMDA reducedA generation in culture. This reduc-
tion in A was associated with activated ERK and nonamyloido-
genic processing of APP. Ironically, our in vivo data are consistent
with both of these studies. We propose that the difference be-
tween these studies may be the degree of ERK activation or an-
other component of that signaling cascade. NMDA-R expression
or activity could shift the balance between the A generation and
Figure 5. The ERK signaling cascade is required for NMDA-R-dependent reductions in A generation. A, BAPTA-AM (100M)
was infused into the hippocampus by reversemicrodialysis to chelate calcium. BAPTA-AMalone increased ISF A levels by 27.1
8.3% (p 0.05, n 5).B, At hour 14 from initial treatment, 1MNMDA coinfusedwith BAPTA-AMdid not change ISF A levels
compared to BAPTA-AM alone (n 4) and 40M NMDA with BAPTA-AM only reduced A levels by 30.0 4.9% compared to
BAPTA-AMalone (p 0.001, n 5). C, MEK inhibitor (PD98059, 100M) and ERK inhibitor (FR180204, 100M) infused into the
hippocampus increased ISF A levels by 58.6 19.0% (p 0.01) and 42.4 8.1% (p 0.01), respectively, by 12 h after
administration (n 5–6 per group). D, Instead of decreasing A, 40 M NMDA further increased ISF A levels when in the
presence of either of these inhibitors (112.9 8.5% and 210.5 47.8%, respectively). KN-93, a CaMK inhibitor, did not alter ISF
A levels alone or in the presence of NMDA. Neither the MEK nor ERK inhibitor altered the effect of 1M NMDA on ISF A levels
(data not shown). &Significantly different from vehicle treatment. #Significantly different from each inhibitor alone. E, TTX was
infused into the hippocampus for 16 h, followed coinfusion of FR180204 for 6 h, then addition of 40 M NMDA for 6 h. In this
setting, ISF A levels did not change compared to A levels during TTX and FR180204 alone (n 4). F, PS1APPmicewere treated
with a Trk-B receptor agonist (DHF, 20M) or allopregnanolone (10M) by reverse microdialysis but did not alter ISF A levels.
Serotonin (1mM) infusion reduced ISFAby19.54.1%(p0.05;n5pergroup).DataarepresentedasmeanSEM.*p0.05.
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APP processing mechanisms depending on the dose of NMDA
used and the developmental state in each culture model.
It appears that NMDA-Rs, specifically during prolonged acti-
vation of extrasynaptic receptors, can induce changes in APP
transcription shifting from APP695 transcripts to more amy-
loidogenic APPs that contain a Kunitz protease inhibitor (APP-
KPI) domain (Bordji et al., 2010). While transcriptional changes
may occur in some systems, it is unlikely to be playing a role in
our study given that the PS1APP mice we used overexpress an
APP695 transgene that is not affected by normal APP transcrip-
tional regulation. Our administration of NMDA in these studies
was relatively short-lived (hours), however, so it is possible that
prolonged dosing would have recruited changes in transcription.
Calcium entry through NMDA-Rs can act as a second mes-
senger. Influx of calcium triggers a variety of signaling pathways,
including protein kinase C (PKC), protein kinase A (PKA), and
calcium/calmodulin-dependent kinase II
(CaMKII), all of which can activate ERK
andmay regulate some facet of Ametab-
olism (Chandler et al., 2001; Kawasaki et
al., 2004). Alternatively, for NMDA-Rs
that contain a NR2B subunit, calcium can
cause dissociation of factors physically as-
sociated with the receptor, which leads to
direct activation of the ERK signaling cas-
cade (Krapivinsky et al., 2003; Kim et al.,
2005). Importantly, inhibition of NR2B-
containing receptors only marginally af-
fected A metabolism in our studies,
suggesting that NR2B plays a relatively
minor role in regulation of A metabo-
lism. The subcellular localization of
NMDA-Rs or their subunit composition
may still play critical roles in regulating
A levels, however, in that these factors
can influence when and how ERK activity
is regulated in neurons (Kim et al., 2005;
Ivanov et al., 2006).
ERK signaling and A production
Activated pERK is elevated in the brains
and CSF of AD patients (Perry et al., 1999;
Klafki et al., 2009). These studies propose
that ERK activation is a consequence of
AD-related changes, including oxidative
stress and inflammation; however, the
possibility cannot be discounted that ERK
activity also contributes to AD progres-
sion. Several studies demonstrate that
ERK canmodulate APP processing, suggesting that this signaling
pathway may be a direct factor in AD processes. Decreasing
-secretase or -secretase cleavage or increasing -secretase
cleavage of APP all can reduce A generation. Similar to our
study, ERK has been found to increase -secretase cleavage of
APP (Kojro et al., 2006) as well as reduce -secretase activity.
Inhibition of ERK increases -secretase activity in vitro and in
vivo (Kim et al., 2006). Activated pERK phosphorylates a compo-
nent of the -secretase complex, nicastrin, which appears to re-
duce cleavage activity (Kim et al., 2006; Tung et al., 2008). While
our data show that PS1 protein levels are elevated following
NMDA-R antagonism (Fig. 6D), given that PS1 is not the rate-
limiting component of the complex, it is unclear whether this
would elevate -secretase activity in vivo. These alterations in
-secretase and -secretase both could result in reduced APP
Figure 6. ERK signaling alters processing of APP. CPP (20mg/kg, i.p.) or vehicle (saline)was delivered to PS1APP/mice and brains removed 8 h later for biochemical analysis (n 8mice per
group). A, ERK2 total protein levels did not change following CPP treatment; however, phospho-MEK1/2 and phospho-ERK2 protein levels were reduced by 24.2 9.6% and 29.0 10.7%,
respectively (p 0.05). B, Full-length APP protein levels, as assessed by SDS-PAGE/Western blot, were not altered by CPP treatment. However, total presenilin-1 protein levels were significantly
increased by 26.7 1.9% (p 0.05). C,-Secretase enzymatic activity was decreased by 8.9 1.3% compared to vehicle-treatedmice (p 0.05), whereas-secretase activity was unaltered.
D, Data are presented as mean SEM. *p 0.05.
Figure 7. Model of synaptic mechanisms that regulate A metabolism. A, Synaptic A generation: NMDA infusion into the
hippocampus increases synaptic activity andelevatesAgeneration and then secretion. APPprocessingprogresses normally here,
but at an increased rate.B, Synaptic modulation of APP processing: high levels of NMDA-R activation cause calcium influx into the
neuron, which activates the ERK signaling cascade. ERK enhances-secretase cleavage of APP, thus reducing APP processing into
A. The balance between synaptic generation and APP processing determineswhether overall ISF A levels increase or decrease,
respectively.
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processing into A; however, whether ERK also induces other
changes that impact Ametabolism is unknown.
Use of ERK signaling as a treatment strategy for AD
NMDA-R agonists are unlikely to be a viable chronic therapy for
AD given the role of these receptors in neuronal transmission,
synaptic plasticity, and excitotoxicity. However, it is ultimately
ERK signaling that is responsible for suppression of A levels;
NMDA-R activation is only onemeans bywhich this can occur. It
is possible that activation of ERKvia othermeans could be used to
depress A levels therapeutically. Calcium influx through
NMDA-Rs has been shown to activate ERK (Bading and Green-
berg, 1991; Krapivinsky et al., 2003). The cellular context in
which ERK is activated dictates the downstream effects of this
kinase; thus, not all ERK activators may lower A levels to a
similar extent (Pouysse´gur et al., 2002).Dopamine,metabotropic
glutamate, and serotonin neurotransmitter receptors have also
been linked to ERK activation [for review, see Sweatt (2001) and
Cowen (2007)], as well as awide range of othermolecules, such as
growth factors, integrins, and neurosteroids. In this study, only a
subset of these receptors lead to depressed A levels. There are
currently several drugs, including some approved by the FDA for
use in humans, that target receptors that may be capable of acti-
vating ERK in vivo. Such drugs may contribute to disease risk by
altering A levels over a lifetime. Compounds that activate ERK
within the brain may also be candidate preventative or therapeu-
tic agents capable of lowering A and reducing ADplaque patho-
genesis or growth.
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